Loading stock…

The Chemours Company (CC) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

The Chemours Company

CCMarket cap $2.10BPrice $14.0

Country🇺🇸United States

SectorMaterials

IndustryChemicals

Manufactures titanium dioxide pigments, refrigerants, and industrial chemicals used in paints, cooling systems, and electronics manufacturing worldwide. Spun off from DuPont in 2015, it now supplies nearly every major automaker's refrigerant needs through its Opteon product line.

In Bastion Portfolios?

52W Return+10%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)-5%2

Revenue Forecast

Rev CAGR (1y)+2%3

Rev CAGR (3y)+3%3

Rev CAGR (5y)+3%2

Earnings Forecast

EPS Growth Y+10%5

EPS Growth Y+2+86%10

EPS Growth Y+3+22%8

Quality

Margins

EBIT Margin3%2

Net Income Margin-5%1

Free Cash Flow Margin4%4

Debt

Net Debt/EBITDA5.41

Efficiency

ROE-257%1

ROA-4%1

Earnings Stability44

GEAR+VERY WEAK9

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)89

P/E Ratio (Forward 3y)610

P/BVna–

EV Multiples

EV/EBITDA Fwd78

EV/EBIT Fwd118

Yield

Free Cash Flow Yield10.4%9

Dividend Yield2.5%6

Momentum

Short term

1 month return-10%3

3 month return-24%1

YTD return+20%8

Mid term

Price vs 52wHigh49%1

1 year return-5%4

Long term

3 year return-41%1

5 year return-47%2

Risk Shield

Price Risk

Beta1.61

Volatility64%2

Free Cash Flow

Free Cash Flow Margin4%4

Free Cash Flow Yield10.4%9

Quality

ROCE3%2

Earnings Stability44

Net Debt/EBITDA5.41

02Growth

Is it actually growing, and how fast?

CCThe Chemours

Revenue FY25$5.8B

GROWTH RATING↗

WEAK21 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-5%2

Revenue, next 1Y+2%3

Revenue, next 3Y, CAGR+3%3

Revenue, next 5Y, CAGR+3%2

EARNINGS FORECAST▾SCORE

EPS growth, FY26E0%5

EPS growth, FY27E+86%10

EPS growth, FY28E+22%8

GROWTH ASSESSMENT

STRENGTHS

None flagged.

WATCH

After shrinking over the last 3 years, revenue is set to grow 3%/yr from here.

WEAKNESSES

Growth is the weak spot here, trailing 79% of companies worldwide.

Revenue fell 5%/yr over the last 3 years, behind 80% of companies worldwide.2/10

Revenue is set to grow 3%/yr over the next 3 years, behind most of the market.3/10

Over five years revenue is set to grow 3%/yr, behind 80% of companies worldwide.2/10

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Stalled Business

Growth is a weak point here: a business that's turning around. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY WEAK4 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-10%3

3-month return-24%1

YTD return+20%8

MID & LONG-TERM▾SCORE

% of 52-week high49%1

1-year return-5%4

3-year return-41%1

5-year return-47%2

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming so far this year (+20%).

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-41% over three years and -47% over five), behind 80% of the market.

It's down 5% over the past year, now 51% below its 52-week high. That is lagging the market.

The stock is underperforming over the past month (-10%) and over three months (-24%).

BOTTOM LINE

Falling Knife

Returns rank poorly over both the short and long run, and the price is still falling. Momentum is firmly negative — catching this is a bet against the tape, not with it. Wait for a base to form. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on The Chemours Company. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

CCThe Chemours

Revenue FY25$5.8B

GROWTH RATING↗

WEAK21 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-5%2

Revenue, next 1Y+2%3

Revenue, next 3Y, CAGR+3%3

Revenue, next 5Y, CAGR+3%2

EARNINGS FORECAST▾SCORE

EPS growth, FY26E0%5

EPS growth, FY27E+86%10

EPS growth, FY28E+22%8

GROWTH ASSESSMENT

STRENGTHS

None flagged.

WATCH

After shrinking over the last 3 years, revenue is set to grow 3%/yr from here.

WEAKNESSES

Growth is the weak spot here, trailing 79% of companies worldwide.

Revenue fell 5%/yr over the last 3 years, behind 80% of companies worldwide.2/10

Revenue is set to grow 3%/yr over the next 3 years, behind most of the market.3/10

Over five years revenue is set to grow 3%/yr, behind 80% of companies worldwide.2/10

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Stalled Business

Growth is a weak point here: a business that's turning around. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY WEAK4 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-10%3

3-month return-24%1

YTD return+20%8

MID & LONG-TERM▾SCORE

% of 52-week high49%1

1-year return-5%4

3-year return-41%1

5-year return-47%2

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming so far this year (+20%).

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-41% over three years and -47% over five), behind 80% of the market.

It's down 5% over the past year, now 51% below its 52-week high. That is lagging the market.

The stock is underperforming over the past month (-10%) and over three months (-24%).

BOTTOM LINE

Falling Knife

04Value

Are you paying a fair price for it?

Stop guessing on The Chemours Company. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community